Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Year: 2025
Type: other
Abstract: Baseline tumor H-score levels for AXL positivity by best confirmed overall response per investigator assessment in expansion cohorts. (A) Cohort 3 (Q3W): melanoma with BRAF V600 mutation; (B) cohort 4 (Q3W): melanoma with BRAF V600 wild-type; (C) cohort 5 (Q3W): sarcoma; (D) cohort 6 (3Q4W): other metastatic solid tumors; and (E) cohort 7 (Q3W): platinum-resistant ovarian cancer . CR, complete response; PD, progressive disease; PR, partial response; Q3W, once every 3 weeks; 3Q4W, 3 weekly doses every 4 weeks; SD, stable disease
Authors: Kristoffer Staal Rohrberg, Juanita S. Lopez, Mohammed M. Milhem, Christian U. Blank, Irene Reijers, Fiona Thistlethwaite, Ruth Plummer, Sarina A. Piha-Paul, Pasi A. Jänne, Elaine Shum, Heather M. Shaw, Philip R. Debruyne, Cristopher Lao, Jean-Francois Baurain, Jennifer H. Choe, Eelke Gort, Yujie Zhao, Guy Jerusalem, Patrick Schöffski, Andrew William Chen, Eric A. Cohen, Walter C. Mankowski, Leonid Roshkovan, Sharyn I. Katz, Despina Kontos, Lauren K. Brady, Mohammed Qutaish, Patricia Garrido Castro, Nora Pencheva, Gaurav Bajaj, Yali Fu, Kristian Windfeld, Panagiota Reiter, Maria Jure-Kunkel, Brandon W. Higgs, Katayoun I. Amiri, Tahamtan Ahmadi, Ulf Forssmann, Suresh S. Ramalingam, Ignace Vergote
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4416727617
Cites:
Cited by:
Related to: